Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 30 June 2021 (Q4 FY21), along with the Company's Appendix 4C cash flow report.
Anatara Lifesciences (ASX:ANR), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to announce the transition of Dr David Brookes from Non-Executive Director to Chairman.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities.
Anatara Lifesciences (ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company's Appendix 4C cash flow report.
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial on the effects of 3FDC dietary supplementation on psychological functioning in an adult population.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled "Anti-diarrhea formulation which avoids antimicrobial resistance".
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.
On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.
